Firms to investigate RNAi for Huntington's disease

12/27/2010 | Wall Street Journal, The

Alnylam Pharmaceuticals and Medtronic have teamed up to develop a treatment for Huntington's disease using RNA interference, which can focus on a gene responsible for the production of disease-causing proteins. Medtronic will develop a catheter or a pump that can deliver Alnylam's short, interfering RNA drug directly to the correct area of the brain.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA